- Home
- RWAY vs RXST Comparison
RWAY vs RXST Comparison
Compare RWAY & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RWAY | RXST |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 355.9M | 417.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RWAY | RXST |
|---|---|---|
| Price | $9.15 | $11.78 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 11 |
| Target Price | $11.08 | ★ $11.20 |
| AVG Volume (30 Days) | 453.9K | ★ 859.5K |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | ★ 15.32% | N/A |
| EPS Growth | ★ 44.67 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | $141,071,000.00 | ★ $142,085,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.71 |
| P/E Ratio | $6.16 | ★ N/A |
| Revenue Growth | N/A | ★ 10.75 |
| 52 Week Low | $8.35 | $6.32 |
| 52 Week High | $11.73 | $46.77 |
Technical Indicators
Market Signals| Indicator | RWAY | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 41.19 | 70.47 |
| Support Level | $8.59 | $11.20 |
| Resistance Level | $9.28 | $10.12 |
| Average True Range (ATR) | 0.27 | 0.69 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 38.64 | 89.29 |
Price Performance
Historical ComparisonAbout RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.